PURPOSE: This study was undertaken to evaluate the feasibility and therapeutic effect of high-dose chemoradiotherapy with autologous or allogeneic bone marrow transplantation (BMT) in patients with advanced chronic lymphocytic leukemia (CLL) who relapse after fludarabine treatment. PATIENTS AND METHODS: Twenty-two patients with advanced CLL received high-dose cyclophosphamide, total-body irradiation, and BMT. Eleven patients with relapsed CLL received autologous BMT with marrow collected during a prior fludarabine-induced remission; leukemia cells were depleted from the autologous marrow in seven patients using an anti-CD19 monoclonal antibody and immunomagnetic separation. Eleven patients received allogeneic or syngeneic BMT, seven of whom had refractory Rai stage III or IV disease. RESULTS: Six autologous transplant recipients achieved a complete remission (CR), four a nodular CR (nCR), and one a partial remission (PR). Two recurred with CLL, and three developed Richter's transformation. Two patients had recurrence of immune cytopenias while in morphologic remission; one of these patients died of cytomegalovirus pneumonia. Six of 11 patients survive in remission 2 to 29 months following BMT. Of the 11 patients who received allogeneic or syngeneic BMT, seven achieved a CR, two a nCR, and one a PR; 10 survive 2 to 36 months following BMT. CONCLUSION: These data indicate that high-dose chemotherapy with allogeneic BMT is effective at producing CRs in patients with CLL. Autologous transplantation in CLL is feasible and is capable of producing remissions in patients with advanced CLL. Further studies are warranted to assess the role of BMT in the treatment of CLL.
PURPOSE: This study was undertaken to evaluate the feasibility and therapeutic effect of high-dose chemoradiotherapy with autologous or allogeneic bone marrow transplantation (BMT) in patients with advanced chronic lymphocytic leukemia (CLL) who relapse after fludarabine treatment. PATIENTS AND METHODS: Twenty-two patients with advanced CLL received high-dose cyclophosphamide, total-body irradiation, and BMT. Eleven patients with relapsed CLL received autologous BMT with marrow collected during a prior fludarabine-induced remission; leukemia cells were depleted from the autologous marrow in seven patients using an anti-CD19 monoclonal antibody and immunomagnetic separation. Eleven patients received allogeneic or syngeneic BMT, seven of whom had refractory Rai stage III or IV disease. RESULTS: Six autologous transplant recipients achieved a complete remission (CR), four a nodular CR (nCR), and one a partial remission (PR). Two recurred with CLL, and three developed Richter's transformation. Two patients had recurrence of immune cytopenias while in morphologic remission; one of these patients died of cytomegalovirus pneumonia. Six of 11 patients survive in remission 2 to 29 months following BMT. Of the 11 patients who received allogeneic or syngeneic BMT, seven achieved a CR, two a nCR, and one a PR; 10 survive 2 to 36 months following BMT. CONCLUSION: These data indicate that high-dose chemotherapy with allogeneic BMT is effective at producing CRs in patients with CLL. Autologous transplantation in CLL is feasible and is capable of producing remissions in patients with advanced CLL. Further studies are warranted to assess the role of BMT in the treatment of CLL.
Authors: Uri Rozovski; Ohad Benjamini; Preetesh Jain; Philip A Thompson; William G Wierda; Susan O'Brien; Jan A Burger; Alessandra Ferrajoli; Stefan Faderl; Elizabeth Shpall; Chitra Hosing; Issa F Khouri; Richard Champlin; Michael J Keating; Zeev Estrov Journal: J Clin Oncol Date: 2015-04-06 Impact factor: 44.544
Authors: John G Gribben; David Zahrieh; Katherine Stephans; Lini Bartlett-Pandite; Edwin P Alyea; David C Fisher; Arnold S Freedman; Peter Mauch; Robert Schlossman; Lecia V Sequist; Robert J Soiffer; Blossom Marshall; Donna Neuberg; Jerome Ritz; Lee M Nadler Journal: Blood Date: 2005-08-30 Impact factor: 22.113
Authors: Fatma Visal Okur; Eric Yvon; Ettore Biagi; Gianpietro Dotti; George Carrum; Helen Heslop; Martha P Mims; Joseph C Fratantoni; Madhusudan V Peshwa; Linhong Li; Malcolm K Brenner Journal: Cytotherapy Date: 2011-07-12 Impact factor: 5.414
Authors: Maciej Machaczka; Jan-Erik Johansson; Mats Remberger; Helene Hallböök; Vladimir Lj Lazarevic; Björn Engelbrekt Wahlin; Hamdy Omar; Anders Wahlin; Gunnar Juliusson; Eva Kimby; Hans Hägglund Journal: Med Oncol Date: 2013-11-09 Impact factor: 3.064